• Mabwell secured Chinese NMPA clearance for expanded indications of its MAIWEIJIAN (denosumab) injection to cover bone metastases from solid tumors, also multiple myeloma.
• The biosimilar, positioned against Amgen’s Xgeva, was previously cleared in March 2024 for unresectable giant cell tumor of bone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605202003PR_NEWS_USPR_____CN64405) on May 21, 2026, and is solely responsible for the information contained therein.